Document 336850
KPTI Pipeline Preclinical Phase 1 Later Stage Selinexor (KPT-‐330) Registra&on-‐Directed NHL, DLBCL, Richter’s, MM, WM Hematological Malignancies AML T-‐Cell CML ALL Elderly AML – 2nd -‐Line Richter’s – 2nd -‐Line DLBCL– 3rd -‐Line MM/WM: combo with low dose dexamethasone Solid Tumors Phase 2 Gynecological Malignancies Advanced Tumors Sof Tissue or Bone Sarcomas (Food Effect Study) Glioblastoma Mul&forme Metasta&c Prostate Squamous H&N, Lung, Esoph Wound Healing KPT-‐350, Related SINE Compounds Inflamma&on, Autoimmune & An&-‐viral PAK4 Inhibitors Oncology H1 2015 H1 2015 Mid 2015 We also plan to ini&ate up to two addi&onal registra&on-‐directed trials in hematological or solid tumor indica&ons in late 2014 or early 2015 Current Planned 3 3 ©2014 – Karyopharm Therapeutics, Inc. | Confidential & Proprietary
© Copyright 2024